SCHEMBL2872606

SCHEMBL2872606

COc1cccc(C(=O)NCc2cc3c(-c4cc5ccccc5s4)n[nH]c3cc2F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
RAB9A P51151 2/20 0.46
GAA P10253 2/20 0.46
HPGD P15428 1/20 0.46
CSNK1D P48730 1/20 0.44
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.42
MMP13 P45452 1/20 0.42
ROCK2 O75116 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 1/20 0.41
DHODH Q02127 1/20 0.41
LOX P28300 2/20 0.41
LOXL2 Q9Y4K0 2/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
DGAT2 Q96PD7 1/20 0.41
SENP5 Q96HI0 1/20 0.41
SENP2 Q9HC62 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2866831 0.86 CSNK1D (0.51) SMN1; SMN2RAB9AGAAHPGDCSNK1D
SCHEMBL2864589 0.85 HPGD (0.44) SMN1; SMN2RAB9AGAAHPGDMAPT
SCHEMBL2862635 0.82 DGAT2 (0.56) SMN1; SMN2RAB9AGAAHPGDCSNK1D
SCHEMBL13635380 0.82 SMN1; SMN2 (0.41) SMN1; SMN2GAAHPGDMMP13ROCK2
SCHEMBL6753821 0.77 MAPKAPK2 (0.41) RAB9ANPC1
SCHEMBL2872610 0.75 DGAT2 (0.56) SMN1; SMN2RAB9AGAAHPGDCSNK1D
SCHEMBL2870292 0.74 MAPKAPK2 (0.48) LOXL2
SCHEMBL4341432 0.73 ALDH1A1 (0.47) SMN1; SMN2HPGDMEN1KMT2AUSP2
SCHEMBL13198273 0.73 DGAT2 (0.50) CSNK1DTP53ROCK2DGAT2
SCHEMBL2867630 0.73 SMN1; SMN2 (0.51) SMN1; SMN2RAB9AHPGDCSNK1DMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SMN1; SMN2 4812/4885RAB9A 2355/4885GAA 4805/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SMN1; SMN2 4812/4885RAB9A 2355/4885GAA 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.